ESMO

Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some

September 17th 2024, 3:02pm

Article

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.

Presurgical Cetrelimab With TAR-200 Shows Responses in Muscle-Invasive Bladder Cancer

September 16th 2024, 10:00pm

Article

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.

AI May Predict Cancer Mutations in Lung, Other Cancers

September 16th 2024, 9:00pm

Article

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

Breastfeeding Is OK in Breast Cancer Subset During Hormone Therapy Break

September 16th 2024, 7:00pm

Article

In patients with HR-positive breast cancer who recently gave birth, breastfeeding is OK during a break from receiving hormone therapy.

Targeted Therapy Outperforms Standard Care in Metastatic Solid Cancers

September 16th 2024, 4:29pm

Article

Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.

Therapies for Some With Prostate Cancer Focuses on Reducing Side Effects

September 16th 2024, 3:00pm

Video

At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.

Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC

September 16th 2024, 1:00pm

Article

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.

Perioperative Imfinzi, Neoadjuvant Chemo Improves Survival in Muscle-Invasive Bladder Cancer

September 15th 2024, 10:19pm

Article

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

Enhertu Maintains Quality of Life in Metastatic Breast Cancer Subgroup

September 15th 2024, 8:39pm

Article

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.

Cyramza Plus Lonsurf Did Not Improve Survival in Metastatic Colorectal Cancer

September 15th 2024, 8:00pm

Article

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated metastatic colorectal cancer.